A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety

Journal of Neuroscience

Volumn 28, Issue 49, 2008, Pages 13066-13074

  Furmark, Tomas ^a   Appel, Lieuwe ^b   Henningsson, Susanne ^c   Åhs, Fredrik ^a   Faria, Vanda ^a   Linnman, Clas ^a   Pissiota, Anna ^a   Frans, Örjan ^a   Bani, Massimo ^d   Bettica, Paolo ^d   Pich, Emilio Merlo ^d   Jacobsson, Eva ^e   Wahlstedt, Kurt ^e   Oreland, Lars ^a   Långström, Bengt ^a,b   Eriksson, Elias ^c   Fredrikson, Mats ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d GSK   (Italy)

^e IQVIA   (United States)

Author keywords

Brain; Functional neuroimaging; Genes; Phobia; Placebo; Serotonin

Indexed keywords

ANXIOLYTIC AGENT; PLACEBO; SEROTONIN TRANSPORTER; TRACER; TRYPTOPHAN HYDROXYLASE 2; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

ADULT; ALLELE; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; ANXIETY DISORDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MENTAL STRESS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEOTIDE SEQUENCE; PLACEBO EFFECT; SCINTISCANNING;

ADULT; AMYGDALA; ANXIETY DISORDERS; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBO EFFECT; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS, PSYCHOLOGICAL; TRYPTOPHAN HYDROXYLASE; YOUNG ADULT;

EID: 58149390186     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2534-08.2008     Document Type: Article

References (59)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, Ed 4. Washington, DC: American Psychiatric Press.
2. Arce E, Miller DA, Feinstein JS, Stein MB, Paulus MP (2006) Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology 189:105-116.
3. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP (2008) Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology 196:661-672.
4. Bauman MD, Amaral DG (2005) The distribution of serotonergic fibers in the macaque monkey amygdala: an immunohistochemical study using antisera to 5-hydroxytryptamine. Neuroscience 36:193-203.
5. Beecher HK (1955) The powerful placebo. JAMA 159:1602-1606.
6. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK (2005) Neurobiological mechanisms of the placebo effect. J Neurosci 25:10390-10402.
7. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR (2008) Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 33:3221-3225.
8. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, Hariri AR (2005) A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 10:884-888.
9. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP (2005) Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 112:1479-1485.
10. Canli T, Congdon E, Todd Constable R, Lesch KP (2008) Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol Psychol 79:118-125.
11. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, Kersting A, Arolt V, Heindel W, Deckert J, Suslow T (2007) Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 6:672-676.
12. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164-1166.
13. Faria V, Fredrikson M, Furmark T (2008) Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol 18:473-485.
14. First MB, Gibbon M, Spitzer RL, Williams JBW (1998) SCID-I: interview protocol (in Swedish). Stockholm: Pilgrim.
15. Fisher PM, Meltzer CC, Ziolko SK, Price JC, Moses-Kolko EL, Berga SL, Hariri AR (2006) Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci 9:1362-1363.
16. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210.
17. Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, Andrew CM, Pich EM, Williams PM, Reed LJ, Mitterschiffthaler MT, Suckling J, Bullmore ET (2004) Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61:877-889.
18. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Långström B, Fredrikson M (2002) Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59:425-433.
19. Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Långström B, Oreland L, Fredrikson M (2004) Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 362:189-192.
20. Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergström M, Pich EM, Nilsson LG, Bani M, Långström B, Fredrikson M (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58:132-142.
21. Gelernter J, Kranzler H, Cubells JF (1997) Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101:243-246.
22. Goossens L, Sunaert S, Peeters R, Griez EJ, Schruers KR (2007) Amygdala hyperfunction in phobic fear normalizes after exposure. Biol Psychiatry 62:1119-1125.
23. Hariri AR, Holmes A (2006) Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 10:182-191.
24. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297:400-403.
25. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006) Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59:816-820.
26. Herrmann MJ, Huter T, Müller F, Mühlberger A, Pauli P, Reif A, Renner T, Canli T, Fallgatter AJ, Lesch KP (2007) Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on emotional processing. Cereb Cortex 17:1160-1163.
27. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, Kochunov PV, Nickerson D, Mikiten SA, Fox PT (2000) Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10:120-131.
28. Liebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiatry 22:141-173.
29. Lorberbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, Hamner MB, Ballenger JC, Lydiard RB, Brodrick PS, Bohning DE, George MS (2004) Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 15:2701-2705.
30. Mai JK, Assheuer J, Paxinos G (2004) Atlas of the human brain. San Diego: Elsevier Academic.
31. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19:1233-1239.
32. Mattick RP, Clarke JC (1998) Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 36:455-470.
33. Mayberg H, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA (2002) The functional neuroanatomy of the placebo effect. Am J Psychiatry 159:728-737.
34. Muthen LK, Muthen BO (2008) Mplus user's guide, Ed 5. Los Angeles: Muthen and Muthen.
35. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB (2005) Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62:282-288.
36. Peres JF, Newberg AB, Mercante JP, Simão M, Albuquerque VE, Peres MJ, Nasello AG (2007) Cerebral blood flow changes during retrieval of traumatic memories before and after psychotherapy: a SPECT study. Psychol Med 37:1481-1491.
37. Petrovic P, Kalso E, Petersson KM, Ingvar M (2002) Placebo and opioid analgesia: imaging a shared neuronal network. Science 295:1737-1740.
38. Petrovic P, Dietrich T, Fransson P, Anderson J, Carlsson K, Ingvar M (2005) Placebo in emotional processing: induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46:957-969.
39. Phan KL, Fitzgerald DA, Nathan PJ, Tancer ME (2006) Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry 59:424-429.
40. Raftery AE (1993) Bayesian model selection in structural equation models. In: Testing structural equation models (Bollen KA, Long JS, eds), pp 163-180. Newbury Park, CA: Sage Publications.
41. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leibach FH (2002) Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732.
42. Rhodes RA, Murthy NV, Dresne MA, Selvaraj S, Stavrakakis N, Babar S, Cowen PJ, Grasby PM (2007) Human 5-HT transporter availability predicts amygdala reactivity in vivo. J Neurosci 27:9233-9237.
43. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2007) Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55:325-336.
44. Serretti A, Calati R, Mandelli L, De Ronchi D (2006) Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 7:1659-1669.
45. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 [Suppl 20]:22-33.
46. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA (2001) Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 50:651-658.
47. Sher L (1998) The role of the endogenous opioid system in the pathogenesis of anxiety disorders. Med Hypotheses 50:473-474.
48. Smolka MN, Schumann G, Wrase J, Grüsser SM, Flor H, Mann K, Braus DF, Goldman D, Büchel C, Heinz A (2005) Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 25:836-842.
49. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67:1741-1746.
50. Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG (2002) Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 59:1027-1034.
51. Stein MB, Seedat S, Gelernter J (2006) Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology 187:68-72.
52. Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. Stuttgart, Germany: Georg Thieme Verlag.
53. Tillfors M, Furmark T, Marteinsdottir I, Fischer H, Pissiota A, Långström B, Fredrikson M (2001) Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET-study. Am J Psychiatry 158:1220-1226.
54. Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M (2002) Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry 52:1113-1119.
55. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD (2004) Placebo induced changes in fMRI in the anticipation and experience of pain. Science 303:1162-1167.
56. Wager TD, Scott DJ, Zubieta JK (2007) Placebo effects on human μ-opioid activity during pain. Proc Natl Acad Sci U S A 104:11056-11061.
57. Whalen PJ, Johnstone T, Somerville LH, Nitschke JB, Polis S, Alexander AL, Davidson RJ, Kalin NH (2008) A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 63:858-863.
58. Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR (2003) Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 33:611-622.
59. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS (2005) Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci 25:7754-7762.